Stepwise, precision-based management of allergic Bronchopulmonary Aspergillosis/Mycosis: A real-life multicenter study
Main Article Content
Keywords
Allergic Bronchopulmonary Aspergillosis (ABPA), Allergic Bonchopulmonary Mycosis (ABPM), antifungal therapy, omalizumab, systemic corticosteroids
Abstract
Background: Allergic bronchopulmonary aspergillosis (ABPA) and allergic bronchopulmonary mycosis (ABPM) are hypersensitivity disorders characterized by fungal colonization of the airways and exaggerated Th2-mediated immune responses. Despite corticosteroids being the cornerstone of treatment, adverse effects, relapses, and steroid dependence necessitate adjunctive antifungal and biologic therapies. This study aimed to evaluate clinical, functional, and immunologic responses to different treatment combinations in patients with ABPA or ABPM.
Methods: This retrospective, multicenter, cross-sectional study included 70 patients diagnosed with ABPA (n = 54) or ABPM (n = 16) at two tertiary chest disease centers between 2016 and 2023. Patients were grouped according to systemic corticosteroid (SS) use (SS-using vs non-SS) and further subdivided based on treatment composition (antifungal ± biologic therapy vs antifungal alone). Changes in FEV1 (Forced Expiratory Volume in 1 second), Asthma Control Test (ACT) scores, total serum IgE, and peripheral blood eosinophil count (PBEC) before and after treatment were analyzed.
Results: In the SS-using group, combination therapy with antifungal ± biologic agents produced significant improvements in FEV1 (mL and %) and ACT scores, along with substantial reductions in total IgE and PBEC levels (all P < 0.05). Antifungal monotherapy yielded significant reductions in immunologic parameters but no functional improvement. In the non-SS group, changes were minimal across most parameters, except for a modest reduction in total IgE within the antifungal ± biologic subgroup. The most comprehensive clinical and immunologic responses were observed in patients treated with corticosteroids combined with antifungal and biologic therapy.
Conclusion: SS remain the primary therapeutic modality for ABPA, but the addition of antifungal and biologic agents enhances both immunologic and functional recovery. A precision-based, stepwise treatment model—initiating with corticosteroids, followed by antifungal therapy, and incorporating targeted biologics—may optimize long-term outcomes, minimize steroid exposure, and promote sustained remission in ABPA and ABPM.
References
2 Denning DW, Pashley C, Hartl D, Wardlaw A, Godet C, Del Giacco S, et al. Fungal allergy in asthma-state of the art and research needs. Clin Transl Allergy. 2014;4:14. 10.1186/2045-7022-4-14
3 Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280–91. 10.1016/j.jaci.2011.12.970
4 Agarwal R, Sehgal IS, Dhooria S, Muthu V, Prasad KT, Bal A, et al. Allergic bronchopulmonary aspergillosis. Indian J Med Res. 2020;151(6):529–49. 10.4103/ijmr.IJMR_1187_19
5 Agarwal R, Sehgal IS, Muthu V, Denning DW, Chakrabarti A, Soundappan K, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024;63(4):2400061.10.1183/13993003.00061-2024
6 Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: Systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13:936–44.
7 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110(5):685–92. 10.1067/mai.2002.130179
8 Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51:361–70. 10.3109/13693786.2012.738312
9 Schuyler M. The Th1/Th2 paradigm in allergic bronchopulmonary aspergillosis. J Lab Clin Med. 1998;131:194–6. 10.1016/S0022-2143(98)90089-0
10 Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850–73. 10.1111/cea.12141
11 Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: Lessons from 126 patients attending a chest clinic in north India. Chest. 2006;130(2):442–8. 10.1378/chest.130.2.442
12 Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: Staging as an aid to management. Ann Intern Med. 1982;96(3):286–91. 10.7326/0003-4819-96-3-286
13 Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342(11):756–62. 10.1056/NEJM200003163421102
14 Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial. J Allergy Clin Immunol. 2003;111(5):952–7. 10.1067/mai.2003.1388
15 Rapeport WG, Ito K, Denning DW. The role of antifungals in the management of patients with severe asthma. Clin Transl Allergy. 2020;10(1):46. 10.1186/s13601-020-00353-8
16 Moss RB. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J. 2014; 43(5):1487–500. 10.1183/09031936.00139513
17 Voskamp AL, Gillman A, Symons K, Sandrini A, Rolland JM, O’Hehir RE, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2015;3(2):192–9. 10.1016/j.jaip.2014.12.008
18 Jaggi TK, Agarwal R, Tiew PY, Shah A, Lydon EC, Hage CA, et al. Fungal lung disease. Eur Respir J. 2024;64(5):2400803. 10.1183/13993003.00803-2024
19 Chen X, Zhi H, Wang X, Zhou Z, Luo H, Li J, et al. Efficacy of biologics in patients with allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis. Lung. 2024;202(4):367–83. 10.1007/s00408-024-00717-y
20 Sumi T, Suzuki K, Koshino Y, Ikeda T, Yamada Y, Chiba H. Successful treatment of mucus plug due to allergic bronchopulmonary aspergillosis using dupilumab. Cureus. 2024;16(3):e55884. 10.7759/cureus.55884
21 Mümmler C, Kemmerich B, Behr J, Kneidinger N, Milger K. Differential response to biologics in a patient with severe asthma and ABPA: A role for dupilumab? Allergy Astıma Clin Immunol. 2020;16:55. 10.1186/s13223-020-00454-w
22 Agarwal R, Dhooria S, Singh Sehgal I, Aggarwal AN, Garg M, Saikia B, et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018;153(3):656–64. 10.1016/j.chest.2018.01.005
23 Lebrun-Vignes B, Archer VC, Diquet B, Levron JC, Chosidow O, Puech AJ, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol. 2001;51(5):443–50. 10.1046/j.1365-2125.2001.01372.x
24 Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effect of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther. 1998;64(4):363–8. 10.1016/S0009-9236(98)90066-2
25 Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Garg M, et al. A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2022;59(4): 2101787. 10.1183/13993003.01787-2021
